Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is ...

KING OF PRUSSIA, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.11% to $479.79 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 1.59% ...

In the latest quarter, 8 analysts provided ratings for Vertex VERX, showcasing a mix of bullish and bearish perspectives. The table below provides a concise overview of recent ratings by analysts ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

China’s coercive campaign against Taiwan has escalated in recent years. Beijing’s approach has evolved from putting political and economic pressure on the island’s leadership and now ...

the guest presented antiques expert John Baddeley with an unexpected treasure from before World War II. WATCH: Antiques Roadshow guest reacts to valuation of vintage TV set The item was revealed ...

U.S. stocks largely looked past a heated discussion on Friday between U.S. President Donald Trump and Ukrainian President Volodymyr Zelensky in the Oval Office, which saw Trump claim Ukraine was ...

For almost as long as watches have been worn on wrists, watchmakers have strived to make them function in places they probably shouldn’t. Nowhere is that pursuit more glorified or mastered than in the ...